Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Shire’s Gaucher Drug Meets Endpoints | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Shire’s Gaucher Drug Meets Endpoints

Shire achieved positive results from its first Phase III study (TKT032) evaluating the safety and efficacy of velaglucerase alfa, an investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Shire achieved positive results from its first Phase III study (TKT032) evaluating the safety and efficacy of velaglucerase alfa, an investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. Data from a pediatric study and five-year follow-up results from a long-term Phase I/II extension study (TKT025 EXT) in adults also support long-term safety and efficacy of velaglucerase alfa in patients with Type 1 Gaucher disease. Both studies (TKT032 and TKT025 EXT) met their primary end-points.

TKT032 was a 12-month, randomized, double-blind, parallel-group global study in 25 treatment-naive patients aged two and older that evaluated velaglucerase alfa at 45 U/kg and velaglucerase alfa at 60 U/kg. The primary endpoint was change in hemoglobin concentrations from baseline at 60 U/kg. Secondary endpoints for both doses were changes in platelet counts, changes in organ volumes, changes in surrogate markers of Gaucher disease, and for the 45 U/kg dose only, change in hemoglobin concentrations from baseline.

In the 60 U/kg group, statistically significant changes in mean hemoglobin concentration increased 23%; mean platelet count increased 66%; and mean spleen volume decreased 50%. Additionally, mean liver volume decreased 17%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters